Latest Indivior News & Updates

See the latest news and media coverage for Indivior. We track all announcements, press releases, and industry mentions in real time, all in one place.

Indivior

Specialty pharmaceutical company focused on opioid use disorder

indivior.com

Headquarters: Richmond, United States
Company type: Public company
Number of employees: 1,000–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Indivior

In short: Indivior announced a $2.2 billion merger with Supernus Pharmaceuticals and reported strong Q2 2026 growth driven by its flagship drugs.

Company announcements

Yesterday Indivior

Indivior releases Q2 2026 financial earnings report.

The report highlights key financial results and provides access to the full investor presentation and press release.

Yesterday Indivior

Indivior and Supernus to combine in $2.2B merger

The tax-free all-stock merger of equals expects $125M annual cost synergies and will create Supernus, Inc. with Jack Khattar as CEO.

Yesterday Indivior

Indivior reports Q2 2026 financial results and raises guidance

Total net revenue rose 14% to $343 million, with record SUBLOCADE revenue and adjusted EBITDA, and the company announced a merger with Supernus.

April 30 Indivior

Indivior reports Q1 2026 financial results and raises guidance

Net revenue rose 19% to $317M, SUBLOCADE grew 32%, and adjusted EBITDA increased 112%.

Media coverage

Yesterday The Business Journals

Rockville's Supernus Pharmaceuticals merging with Richmond's Indivior - Washington Business Journal

Supernus Pharmaceuticals of Rockville merges with Richmond's Indivior in a deal expected to create a neurological drug company with $2.2 billion in annual revenue.

Yesterday Investing.com

Indivior Q2 2026 slides: SUBLOCADE drives 111% EBITDA surge By Investing.com

Indivior PLC (NASDAQ:INDV) presented its second-quarter 2026 financial results on August 3, revealing substantial margin expansion and accelerating growth in its flagship opioid use disorder...

Yesterday Fierce Pharma

Supernus, Indivior merge to create CNS-focused company and expand BD opportunities

Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have agreed to merge in an all-stock transaction to form a new central nervous system-focused biopharma.

Yesterday Reuters

Supernus, Indivior merge to strengthen neuroscience drug portfolio

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock...

Never miss news about Indivior

Track Indivior and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Indivior competitors & trending companies

Browse news for competitors to Indivior and other trending companies.